Trial Profile
A Pilot Study to Evaluate the Safety and Efficacy of PROCRIT (Epoetin Alfa) 80,000 Units Once Every Four Weeks (Q4W) vs. 40,000 Units Once Every Two Weeks (Q2W) in Cancer Subjects With Non-Chemotherapy Anemia (NCA)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 May 2014
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 19 May 2014 New trial record
- 22 Oct 2007
- 17 Oct 2007